Neuroleptic Malignant Syndrome

Treat the syndrome as presumptive NMS when a patient exposed to an antipsychotic develops the core cluster of hyperthermia, diffuse muscle rigidity, altered mental status, and autonomic instability. Irregular or labile blood pressure, tachycardia, diaphoresis, and dysrhythmia are characteristic autonomic findings; elevated creatine kinase, myoglobinuria, rhabdomyolysis, and acute renal failure are important complications rather than required diagnostic features. accessdata fda+3accessdata fdaThis label may not be the latest approved by FDA. For current ...accessdata fda1 This label may not be the latest approved by FDA. For ...accessdata fdaquetiapine fumarate extended-release tabletsPubMedAn Approach to the Pharmacotherapy of Neuroleptic ... - PMC

The temporal relationship to dopamine blockade is a major discriminator. NMS is typically reported within 24 to 72 hours of exposure and is uncommon after 2 weeks, although depot formulations can extend the exposure window. Do not exclude NMS because the agent is an atypical antipsychotic: paliperidone, olanzapine, quetiapine, and clozapine labeling each describes NMS. accessdata fda+4accessdata fdaThis label may not be the latest approved by FDA. For current ...accessdata fda1 This label may not be the latest approved by FDA. For ...accessdata fdaquetiapine fumarate extended-release tabletsdailymed nlm nihCLOZARIL- clozapine tablet TYA PharmaceuticalsScienceDirectDifferential Diagnosis Between Neuroleptic Malignant Syndrome and Catatonia - ScienceDirect

Escalate immediately to a monitored or ICU setting for hyperthermia with rigidity, delirium or reduced consciousness, autonomic lability, significant creatine kinase elevation, myoglobinuria, renal dysfunction, respiratory compromise, or inability to maintain airway protection. ICU care is used to provide aggressive hydration, electrolyte correction, cooling, and cardiorespiratory support. PubMed+3PubMedAn Approach to the Pharmacotherapy of Neuroleptic ... - PMCPubMedEmergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using DantrolenePubMedManagement of common adverse effects of antipsychotic ...PubMedDrug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association

Obtain serial temperature, heart rate, blood pressure, respiratory rate, oxygen saturation, mental-status assessments, and focused neuromuscular examinations. Check creatine kinase and leukocyte count as supportive laboratory measures, and evaluate for myoglobinuria and acute renal injury when rhabdomyolysis is suspected. accessdata fda+2accessdata fdaThis label may not be the latest approved by FDA. For current ...accessdata fda1 This label may not be the latest approved by FDA. For ...PubMedDrug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association

Use the consensus hyperthermia threshold of temperature greater than 100.4°F (38.0°C) as a diagnostic criterion, but do not defer treatment when the clinical pattern and exposure history are compelling before full hyperthermia develops. Rigidity may precede hyperthermia, and atypical presentations have been described with incomplete expression of the classic features. PubMed+2PubMedAn international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method - PubMedScienceDirectMajor symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports - ScienceDirectScienceDirectAtypical neuroleptic malignant syndrome: A systematic review of case reports - ScienceDirect

The diagnostic task is not merely to label fever and elevated creatine kinase as NMS. FDA labeling specifically directs clinicians to identify serious medical illness, including pneumonia and systemic infection, and untreated or inadequately treated extrapyramidal symptoms. Consider central anticholinergic toxicity, heat stroke, drug fever, and primary CNS pathology in parallel. accessdata fda+2accessdata fdaThis label may not be the latest approved by FDA. For current ...accessdata fda1 This label may not be the latest approved by FDA. For ...accessdata fdaquetiapine fumarate extended-release tablets

Immediately discontinue all antipsychotic drugs and other nonessential concurrent medications. Begin active cooling for hyperthermia, aggressive intravenous hydration for rhabdomyolysis risk, correction of electrolyte abnormalities, and cardiorespiratory support. Address coexisting serious medical illness with its specific therapy rather than attributing every abnormality to NMS. accessdata fda+3accessdata fdaThis label may not be the latest approved by FDA. For current ...PubMedAn Approach to the Pharmacotherapy of Neuroleptic ... - PMCPubMedManagement of common adverse effects of antipsychotic ...PubMedDrug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association

Use benzodiazepines for agitation, delirium, or possible catatonia. Lorazepam 1 to 2 mg IM or IV every 4 to 6 hours is described for mild or early NMS; diazepam 10 mg IV every 8 hours is another reported regimen. Monitor for sedation and hypotension. PubMedPubMedAn Approach to the Pharmacotherapy of Neuroleptic ... - PMC

For moderate NMS, add a dopamine-enhancing strategy when supportive care and benzodiazepines are insufficient. Bromocriptine 2.5 mg by nasogastric tube every 8 to 12 hours may be titrated to a maximum of 45 mg/day; amantadine 200 to 400 mg/day in 2 or 3 divided doses is an alternative. Bromocriptine can cause hypotension, gastrointestinal adverse effects, and psychosis; amantadine can cause orthostatic hypotension and agitation. PubMed+1PubMedAn Approach to the Pharmacotherapy of Neuroleptic ... - PMCPubMedDrug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association

For severe rigidity and hyperthermia, dantrolene is commonly used with supportive care and bromocriptine. Reported regimens include an IV 1 mg/kg bolus followed by 1 mg/kg IV every 6 hours; dosing has varied in published cases, reflecting the absence of consistent treatment guidelines. PubMed+2PubMedEmergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using DantrolenePubMedManagement of common adverse effects of antipsychotic ...PubMedDrug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association

Consider ECT when NMS is refractory to withdrawal, supportive care, and pharmacologic treatment, or when malignant catatonia remains likely and requires definitive treatment. This decision requires psychiatric, anesthesia, and critical-care coordination in medically unstable patients. PubMed+1PubMedManagement of common adverse effects of antipsychotic ...NeurologyA 17-Year-Old Adolescent Boy With New Altered Mental ...

Before rechallenge, document the suspected trigger, exposure timing, dose changes, coadministered dopamine-blocking agents, acute complications, and alternative diagnoses considered. Correct reversible contributors such as dehydration, infection, electrolyte disturbance, and untreated extrapyramidal symptoms before again exposing the patient to dopamine blockade. accessdata fda+3accessdata fdaThis label may not be the latest approved by FDA. For current ...accessdata fda1 This label may not be the latest approved by FDA. For ...accessdata fdaquetiapine fumarate extended-release tabletsPubMedManagement of common adverse effects of antipsychotic ...

If antipsychotic treatment remains necessary, delay reintroduction as long as clinically feasible after resolution; a longer interval from recovery to rechallenge is associated with lower recurrence risk. Reported recurrence risk is approximately 10% to 40%, so the restart plan should explicitly balance psychiatric relapse risk against recurrent NMS. PubMedPubMedManagement of common adverse effects of antipsychotic ...

Select a lower-D2-potency antipsychotic such as quetiapine or clozapine, begin at a very low dose, titrate gradually, and monitor closely for recurrent rigidity, fever, autonomic change, mental-status deterioration, and creatine kinase elevation when clinically indicated. Atypical agents are not risk-free: NMS is described in labeling for quetiapine, olanzapine, paliperidone, and clozapine. PubMed+4PubMedManagement of common adverse effects of antipsychotic ...accessdata fdaThis label may not be the latest approved by FDA. For current ...accessdata fda1 This label may not be the latest approved by FDA. For ...accessdata fdaquetiapine fumarate extended-release tabletsdailymed nlm nihCLOZARIL- clozapine tablet TYA Pharmaceuticals

In Parkinson disease and other extrapyramidal disorders, abrupt withdrawal of levodopa or other dopaminergic therapy can produce an NMS-like syndrome. In a rigid, febrile, autonomically unstable patient with parkinsonism, establish whether dopaminergic medication was interrupted as well as whether a dopamine blocker was introduced. NeurologyNeurologyManagement of Parkinson's disease

In pediatric anti-NMDA receptor encephalitis, antipsychotics may worsen dyskinesia or induce NMS; severe behavioral dysregulation with dyskinesia and autonomic instability should therefore prompt reassessment for autoimmune encephalitis and prioritization of treatment for the underlying disease. NeurologyNeurologyInternational Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis

For patients with dementia-related psychosis, note that antipsychotic product labeling also carries safety concerns regarding increased mortality and cerebrovascular adverse events; NMS recognition should not obscure medication-specific risk-benefit reassessment after recovery. accessdata fda+1accessdata fda1 This label may not be the latest approved by FDA. For ...accessdata fdaquetiapine fumarate extended-release tablets